Food and Drug Administration
Transmissible Spongiform Encephalopathies Advisory Committee
June 26, 2002
Slides
Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Inteded for Transplantation, TSEAC ppt
Risk Assessments, Dr. Rolf Taff, PhD, FDA ppt
Global Tally of Iatrogenic CJD doc
Implications of Batch Processing for Manufacture of Human Cells , Tissues & Cellular & Tissue-Based Products ppt
Limiting Batch Size; Effects of Batch Size on Risk of Contamination with Infectious Agents, Dr. Thomas Lynch, JD, PhD, Regulatory and Quality ppt
AATB Standards on Recovery & Processing Human Tissue ppt
Safety Steps in Eye Banking, Ellen Heck, MT, MA, CEBT ppt
Disinfection & Sterilization of TSE Contaminated Surgical Instruments Dr. Robert Rohwer, PhD, VA Medical Ctr, Baltimore, MD pdf
Evaluation of Viral Clearance Studies, Dr. Mahmood Farshid, PhD, FDA ppt
Validation of Bone Allograft Processing, Richard Russo, Osteotech, Inc. ppt
Validation of the BioCleanse Tissue Sterilization Process, Dr. C. Randal Mills, PhD ppt
Perspective on TSE Clearance Studies, Dr. Robert Rohwer, PhD, VA Medical Ctr, Baltimore, MD pdf
Draft Guidance: Preventive Measures to Reduce the Possible Risk of Transmission of CJD & cCJD by Human Cells, Tissues, and Cellular & Tissue-Based Products ppt
Identification and Deferral of Tissue Donors for Possible BSE/vCJ-D Expososure: Estimating the Impact, Dr. Alan Williams, PhD, FDA ppt